BioMarin Pharmaceutical Inc. (BMRN)
$
57.81
-0.32 (-0.55%)
Key metrics
Financial statements
Free cash flow per share
4.3382
Market cap
11.1 Billion
Price to sales ratio
0
Debt to equity
0.0998
Current ratio
4.8276
Income quality
1.2944
Average inventory
1.4 Billion
ROE
0.0046
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
BioMarin Pharmaceutical Inc. specializes in the development and commercialization of therapies aimed at addressing serious and life-threatening rare diseases and medical conditions. The company’s portfolio includes Vimizim, an enzyme replacement therapy for mucopolysaccharidosis (MPS) IV type A; Naglazyme, a recombinant enzyme for treating MPS VI; and Kuvan, a synthetic oral treatment for phenylketonuria (PKU). Additionally, the product lineup features Palynziq, which is a PEGylated recombinant enzyme administered via subcutaneous injection to lower blood Phe levels; Brineura, designed for ceroid lipofuscinosis type 2; and Voxzogo, a daily injection aimed at treating achondroplasia. Another key product, Aldurazyme, is a purified protein mimicking the natural human enzyme alpha-L-iduronidase. BioMarin is also progressing with valoctocogene roxaparvovec in Phase III trials for severe hemophilia A, BMN 307 in Phase 1/2 trials for PKU, and BMN 255 in Phase 1/2 trials targeting primary hyperoxaluria. The total costs and expenses for the company are $0.00 reflecting its overall spending. The gross profit ratio is 0.00 indicating the efficiency of the company's production and sales operations. Furthermore, the company recorded a net income of $26,785,000.00 highlighting its profitability. Depreciation and amortization expenses of $0.00 are reported, reflecting the wear and tear of its assets, against a substantial revenue of $0.00 showcasing its strong market presence. As a publicly traded entity, BioMarin's stock is reasonably priced at $54.36 appealing to a broad range of investors. The stock maintains a high average trading volume of 2,662,756.00 indicating robust liquidity. With a mid-range market capitalization of $11,106,130,227.00 the company is recognized as a steady performer. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Additionally, BioMarin operates within the Healthcare sector, driving innovation and growth, which positions it favorably among its peers. This dynamic combination of product offerings and market strategies underscores BioMarin's commitment to enhancing the lives of patients facing rare diseases.
Is BioMarin Pharmaceutical Inc. (BMRN) a good investment?
Investing in BioMarin Pharmaceutical Inc. (BMRN) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is BioMarin Pharmaceutical Inc. (BMRN)'s stock forecast?
Analysts predict BioMarin Pharmaceutical Inc. stock to fluctuate between $50.76 (low) and $73.51 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is BioMarin Pharmaceutical Inc.'s market capitalization?
As of 2026-02-09, BioMarin Pharmaceutical Inc.'s market cap is $11,106,130,227, based on 192,114,344 outstanding shares.
How does BioMarin Pharmaceutical Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., BioMarin Pharmaceutical Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy BioMarin Pharmaceutical Inc. (BMRN) stock?
To buy BioMarin Pharmaceutical Inc. (BMRN) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for BMRN. Place an order (Market, Limit, etc.).
What is the best time to invest in BioMarin Pharmaceutical Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did BioMarin Pharmaceutical Inc. perform in the last earnings report?
Revenue: $0 | EPS: $0.14 | Growth: -93.78%.
Where can I find BioMarin Pharmaceutical Inc.'s investor relations reports?
Visit https://www.biomarin.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for BioMarin Pharmaceutical Inc.?
You can explore historical data from here
What is the all-time high and low for BioMarin Pharmaceutical Inc. stock?
All-time high: $117.77 (2023-01-27) | All-time low: $50.76 (2025-11-07).
What are the key trends affecting BioMarin Pharmaceutical Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
defenseworld.net
Savant Capital LLC raised its holdings in BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 54.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 82,827 shares of the biotechnology company's stock after purchasing an additional 29,174 shares during the period.
defenseworld.net
Callan Family Office LLC decreased its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 37.5% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 41,891 shares of the biotechnology company's stock after selling 25,147 shares during the period.
seekingalpha.com
BioMarin Pharmaceuticals recently announced it is acquiring Amicus Therapeutics for $4.8B, adding two rare disease assets with blockbuster potential and strategic synergies. The acquisition provides insurance against competitive threats to Voxzogo, BMRN's key growth driver facing pressure from Ascendis and BridgeBio pipeline advances. The deal is initially slightly dilutive to 2026 non-GAAP EPS but is expected to be substantially accretive from 2027 as synergies and expansion opportunities materialize.
fool.com
BioMarin expects strong sales for its rare-disease drug, Voxzogo, in Q4. The company also has several important catalysts on the way in the first half of the year.
prnewswire.com
SAN RAFAEL, Calif., Jan. 26, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it intends to offer, subject to market and other conditions, $850 million of senior unsecured notes due 2034 (the "Notes").
zacks.com
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
zacks.com
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with BioMarin Pharmaceutical (BMRN) and Tarsus Pharmaceuticals, Inc. (TARS). But which of these two stocks is more attractive to value investors?
zacks.com
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
zacks.com
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
seekingalpha.com
BioMarin Pharmaceutical Inc. (BMRN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
See all news
